Compare Johnson & Johnson (JNJ) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Real Estate Index Fund ETF — how do they compare? Johnson & Johnson trades at $248.46 (market cap $598.96B), while Vanguard Real Estate Index Fund ETF trades at $99.36. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.
| JNJ | VNQ | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $100.07 |
52-Week Low | $164.36 | $87.00 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VNQ trades at $99.5, down 0.52% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF's expense ratio of 0.13% remains a competitive advantage, and recent news highlights its 12% year-to-date total return through mid-July 2026. Dividend payments are scheduled, with the next payout of $0.86 set for June 26, 2026.
Outlook is cautiously optimistic, supported by technical strength and cost efficiency, but risks include sensitivity to interest rates and potential overbought conditions. The ETF's domestic focus offers stability, yet investors should weigh the impact of Treasury yield fluctuations on real estate valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
